TABLE 2.
Bactericidal activities of the peptides for S. aureus and MRSA
| Peptide | LC50a
|
|||
|---|---|---|---|---|
| In vitro
|
In vivo
|
|||
| S. aureus | MRSA | S. aureus | MRSA | |
| Histatin 5 | 8.3 | 2.8 | 1.0 | 3.5 |
| Dh5 | 35.0 | 112.5 | 2.0 | 1.0 |
| Dh5 dimer | 8.4 | 8.2 | 1.5 | 2.0 |
| Dhvar4 | 4.2 | 3.1 | 1.0 | 1.5 |
| Dhvar4 dimer | 0.5 | 0.4 | 1.0 | 1.0 |
| Dhvar5 | 51.0 | 17.3 | 2.0 | 3.0 |
| Dhvar5 dimer | 0.4 | 0.4 | 5.0 | 2.0 |
| P-113 | 12.5 | 18.6 | ND | 3.0 |
| P-113 dimer | 49.8 | 38.9 | ND | 3.0 |
a
Concentration required to reduce viable counts by 50% compared to incubations without peptide (in vitro) (μM) or to reduce viable counts by 50% compared to untreated mice (in vivo) (μmol/g of infected tissue). In vitro results are means from at least three sets of independent experiments; in vivo results are means from at least three independent animals per peptide concentration.